Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine

Healthy Subjects Clinical Trial

Official title:

Study on the Drug Interaction of HS-10234 and Emtricitabine in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04477096
• Other study ID #: HS-10234-108
• Status: Completed
• Phase: Phase 1
• Start date: August 3, 2020
• Est. completion date: September 24, 2020

Study information

• Verified date: July 2020
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine after multiple dose in healthy subjects.

Description:

The study includes two parts. Part 1 is to evaluate the impact of Emtricitabine on HS-10234. Part 2 is to evaluate the impact of HS-10234 on Emtricitabine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: September 24, 2020
• Est. primary completion date: September 24, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Voluntarily sign an informed consent before any activities related to this trial and understand the procedures and methods of this trial;

2. Aged between 18 and 55 years old (including cutoff value), both male and female;

3. Male body weight =50.0kg, female body weight =45.0kg, body mass index (BMI) is 19~26 kg/m2 (including both ends);

4. Those who signed the informed consent form and had no birth plan within 3 months after the last dose and agreed to take effective contraceptive measures.

Exclusion Criteria:

1. People who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other diseases that can interfere with the test results, Or have a stomach problem or have a history of stomach problems;

2. People who have drugs (penicillin or cephalosporin drugs), food, or have a history of allergy to test drugs or similar drugs;

3. If the subject have a history of surgery within the 4 weeks prior to the trial or plan to undergo surgery during the study period or have surgery that affected the absorption, distribution, metabolism, and excretion of drugs;

4. Those who took any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before taking the study drug, or those who were within 5 half-lives of the drug at the time of screening; those who plan to take non-study drugs or health products during the trial;

5. Those who participated in any drug clinical trial and used any trial drug within 3 months before administration (subject to the informed consent);

6. Participate in blood donation within 3 months before administration and the amount of blood donation >200 mL, or have received blood transfusion;

7. Unable or unwilling to follow the lifestyle guidelines required in the plan;

8. Smokers or those who smoked more than 5 cigarettes per day in the 3 months before the trial;

9. Alcoholics or frequent drinkers within 6 months before the test, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) or before administration Alcohol screening positive;

10. People who have a history of drug abuse, drug dependence, or a positive drug screen before administration;

11. Screening/baseline visit to alanine aminotransferase and/or aspartate aminotransferase and/or alkaline phosphatase and/or total bilirubin exceeds 1.2 times the upper limit of normal;

12. Abnormal vital signs (systolic blood pressure <90 mmHg or >140 mmHg, diastolic blood pressure <50 mmHg or >90 mmHg; pulse <50 bpm or >100 bpm) or physical examination, electrocardiogram, laboratory examination, imaging examination, etc. Abnormality has clinical significance (subject to the judgment of the clinical research doctor);

13. The QT interval is prolonged during screening (calculated using Bazett's method, male>450 msec, female>460 msec);

14. Hepatitis B surface antigen, hepatitis C antibody, syphilis serotonin, HIV antibody test positive;

15. Women during pregnancy or lactation;

16. Subjects may not be able to complete the study for other reasons or the investigator believes that they should not be included.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• HS-10234
HS-10234
• Emtricitabine
Emtricitabine

Locations

Country	Name	City	State
China	Xiangya Hospital, Central South University	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine	Cmax	0 - 24 hour on 7th day
Primary	Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine	AUC0-tau	0 - 24 hour on 7th day
Secondary	Concentration of HS-10234's metabolite tenofovir-diphosphate in peripheral blood mononuclear cells.	Concentration	0 - 24 hour on 7th day
Secondary	Incidence of AEs,	laboratory abnormalities (based on hematology, biochemistry, and urinalysis tests)	0 - 23 day
Secondary	Incidence of AEs,	body temperature	0 - 23 day
Secondary	Incidence of AEs,	respiratory rate	0 - 23 day
Secondary	Incidence of AEs,	blood pressure	0 - 23 day
Secondary	Incidence of AEs,	pulse rate	0 - 23 day
Secondary	Incidence of AEs,	Resting 12-lead ECG parameters(ECG QT Interval)	0 - 23 day